We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.



[1] Dawn M. Ecker, Susan Dana Jones, and Howard L. Levine. The therapeutic monoclonal antibody market, MABs, Jan-Feb 2015, 7(1), 9-14 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622599/

[2] Thomas Morrow and Linda Hull Felcone. Defining the difference: What Makes Biologics Unique, Biotechnol Healthc, Sep 2004, 1(4), 24-26, 28-29 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564302/
[3] U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. FOOD AND DRUG ADMINISTRATION, What are “Biologics” Questions and Answers: What is a biological product? How do biological products differ from conventional drugs?, August 5, 2015 https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm

[4] S.W. Chung, T.A. Hil-lal, Y. Byun. Strategies for non-invasive delivery of biologics, J Drug Target, 2012, 20(6), 481–501, https://www.ncbi.nlm.nih.gov/pubmed/22632037

Previous Next
Frederike Ferber

Frederike Ferber

Specialist, TCS, Commercial, EU

Subscribe to receive the latest blog post